The estimated Net Worth of James Patrick Kelly is at least 1.38 百万$ dollars as of 16 August 2024. Mr. Kelly owns over 2,367 units of Supernus Pharmaceuticals Inc stock worth over 486,464$ and over the last 14 years he sold SUPN stock worth over 893,661$. In addition, he makes 0$ as Chief Financial Officer、 Executive Vice President at Supernus Pharmaceuticals Inc.
James has made over 14 trades of the Supernus Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 2,367 units of SUPN stock worth 30,676$ on 16 August 2024.
The largest trade he's ever made was selling 18,857 units of Supernus Pharmaceuticals Inc stock on 2 March 2020 worth over 195,359$. On average, James trades about 2,920 units every 132 days since 2010. As of 16 August 2024 he still owns at least 15,652 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kelly stock trades at the bottom of the page.
James Patrick Kelly has been appointed as Chief Financial Officer, Executive Vice President of the Company effective 10/12/2020. Mr. Kelly has over 25 years of biopharmaceutical industry experience in finance roles of increasing scope and responsibility. Most recently, Mr. Kelly served as Executive Vice-President, Chief Financial Officer and Treasurer of Vanda Pharmaceuticals Inc., a publicly traded pharmaceutical company, from February 2017 through March 2020. Mr. Kelly previously served as Senior Vice-President, Chief Financial Officer and Treasurer of Vanda Pharmaceuticals from December 2010 through February 2017, and its Secretary from December 2010 to September 2015 and again from April 2018 to August 2018. From March 2006 through December 2010, Mr. Kelly was at MedImmune, a biotechnology subsidiary of AstraZeneca Group, first as Director of Sales and Marketing Finance and then as Vice-President and Controller. From June 2000 through December 2005, Mr. Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the Director of Planning and Operations. From June 1997 to June 2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc., which team was responsible for mergers and acquisitions and treasury management. Mr. Kelly began his career in life sciences in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson. Mr. Kelly received his Bachelor of Science degree in Business Administration from the University of Vermont and his Master of Business Administration in Finance from Cornell University and is a Chartered Financial Analyst.
James Kelly is 54, he's been the Chief Financial Officer、 Executive Vice President of Supernus Pharmaceuticals Inc since 2020. There are 14 older and 2 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
James's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, , 20878.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over 37,265,765$ worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth 83,216,588$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of 4,263,834$. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth 652,680$.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: